Achieve Life Sciences: Engagement at the Healthcare Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV) is gearing up for a significant event during a prominent healthcare conference. As a company dedicated to developing solutions for nicotine dependence, Achieve will host in-person meetings as part of the major gathering in January.
Meet Achieve's Leadership
Leading the charge, CEO Rick Stewart will be present to share insights into the company's late-stage cytisinicline program, intended to assist individuals in quitting smoking and vaping. The discussions will not only cover the present condition of their research but also lay out the strategic plans for the forthcoming year.
Progress on Cytisinicline Development
To date, Achieve has achieved substantial milestones in clinical trials, succeeding in two Phase 3 studies involving over 1,600 participants in smoking cessation efforts. They are also advancing in their Phase 2 trial aimed at helping adults who wish to stop vaping. With plans to submit a New Drug Application (NDA) for cytisinicline as a smoking cessation aid in the near future, Achieve is on track for a significant breakthrough in the realm of nicotine addiction treatment.
Upcoming Clinical Trials
In addition to the anticipated NDA submission, Achieve plans to initiate an additional Phase 3 clinical trial focused on vaping cessation. This trial is expected to start in the third quarter of the coming year, further expanding their commitment to addressing nicotine addiction comprehensively.
About Achieve Life Sciences
Achieve Life Sciences is at the forefront of tackling the international challenge of smoking-related health issues. Their flagship drug, cytisinicline, is the focal point of their research and development activities, aimed at providing an effective solution for smokers and vapers alike. The company has previously completed two successful Phase 3 studies supporting the efficacy of cytisinicline for smoking cessation, with further investigations underway to evaluate its impact on vaping.
The Importance of Cytisinicline
Statistics reveal a pressing need for effective nicotine cessation methods. Millions of adults are grappling with nicotine addiction, making it a global health crisis. Cytisinicline, a plant-derived compound, is designed to bind effectively to nicotine receptors in the brain, thereby decreasing withdrawal symptoms and reducing the overall satisfaction derived from nicotine use. This innovative approach highlights Achieve's commitment to transforming the landscape of nicotine addiction treatment.
Company Contact Information
For further details or to arrange a meeting, individuals can reach out to the Achieve Life Sciences investor relations team. Nicole Jones can be contacted via email or phone for inquiries regarding their ongoing projects or business strategies.
Frequently Asked Questions
What is cytisinicline?
Cytisinicline is an investigational drug developed by Achieve Life Sciences aimed at helping individuals quit smoking and vaping by reducing nicotine cravings.
When is Achieve's next clinical trial?
Achieve plans to begin a Phase 3 clinical trial for vaping cessation in the third quarter of the upcoming year.
How can I schedule a meeting with Achieve Life Sciences?
To schedule a one-on-one meeting, please contact the investor relations team directly via email.
What progress has Achieve made in its clinical trials?
Achieve has successfully completed two Phase 3 trials with cytisinicline and a Phase 2 trial focused on vaping cessation.
Who is leading Achieve Life Sciences?
Rick Stewart serves as the Chief Executive Officer, leading the company in its mission to treat nicotine dependence.
